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Abstract: Non-alcoholic fatty liver disease (NAFLD) constitutes the most common liver disease
worldwide, and is frequently linked to the metabolic syndrome. The latter represents a clustering of
related cardio-metabolic components, which are often observed in patients with NAFLD and increase
the risk of cardiovascular disease. Furthermore, growing evidence suggests a positive association
between metabolic syndrome and certain mental health problems (e.g., depression, anxiety, and
chronic stress). Given the strong overlap between metabolic syndrome and NAFLD, and the common
underlying mechanisms that link the two conditions, it is probable that potentially bidirectional
associations are also present between NAFLD and mental health comorbidity. The identification
of such links is worthy of further investigation, as this can inform more targeted interventions for
patients with NAFLD. Therefore, the present review discusses published evidence in relation to
associations of depression, anxiety, stress, and impaired health-related quality of life with NAFLD
and metabolic syndrome. Attention is also drawn to the complex nature of affective disorders and
potential overlapping symptoms between such conditions and NAFLD, while a focus is also placed
on the postulated mechanisms mediating associations between mental health and both NAFLD and
metabolic syndrome. Relevant gaps/weaknesses of the available literature are also highlighted,
together with future research directions that need to be further explored.
Keywords: non-alcoholic fatty liver disease; NAFLD; NASH; metabolic syndrome; insulin resistance;
obesity; depression; anxiety; stress; health related quality of life
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) currently constitutes the most common
chronic liver disease worldwide, representing a “silent epidemic” [1,2]. Indeed, NAFLD
prevalence rates of up to 25–30% have been reported in the general population (depend-
ing on the studied population/cohort and the applied diagnostic criteria/method), with
increasing trends in both developed and developing countries [2–4]. Of note, markedly
higher NAFLD prevalence is noted among adults with obesity [2–4], and is estimated to af-
fect around 70–90% of this population [5]. Given this strong link to obesity, NAFLD is often
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referred to as the hepatic manifestation of metabolic syndrome [6–9]. Denoting a clustering
of interrelated conditions revolving around obesity-related insulin resistance, metabolic
syndrome may include central/abdominal obesity, type 2 diabetes (T2DM), hypertension,
and dyslipidemia [10]. Overall, the escalating prevalence of obesity in recent decades has
led to a dramatic increase in the global prevalence of both metabolic syndrome and NAFLD,
with almost 85% of NAFLD patients also presenting with various metabolic syndrome
components (e.g., insulin resistance and obesity) [3,6,11,12]. Moreover, metabolic syndrome
and its associated cardio-metabolic diseases, including NAFLD, are independently related
to a substantially increased risk of developing cardiovascular disease (CVD) [10,13,14].
Compelling evidence from clinical and epidemiological studies indicates that the
components of metabolic syndrome share common underlying pathogenetic mechanisms,
which are mostly—but not exclusively—driven by obesity and obesity-related insulin
resistance [10,12,15,16]. Because of the strong associations between metabolic syndrome
and NAFLD, the full spectrum of risk factors and the underlying mechanisms that link
them are currently under extensive research [3,10,12,17]. As such, it should be highlighted
that growing evidence supports a direct association between metabolic syndrome and
common mental health disorders (e.g., depression and anxiety) [18–20], in addition to
its well-established associations with other cardio-metabolic conditions. Furthermore,
these affective disorders, as well as chronic stress, have been linked to key components
of metabolic syndrome, such as obesity and T2DM [21–23], which may further adversely
impact cardio-metabolic health and health-related quality of life (HRQoL). Indeed, studies
in both humans and animal models provide growing evidence of the risk of metabolic
syndrome in cases where depressive disorders are present [19,23].
Despite the above noted associations, and although high prevalence rates of such
mood disorders (e.g., depression) have been identified among patients with NAFLD [24,25],
less work has focused on the potential relationship between NAFLD and mental health.
Given the aforementioned close links between NAFLD and metabolic syndrome, the
potential bidirectional associations between NAFLD and common mental health disorders
that may coexist in patients with NAFLD merit further investigation. In this context,
it should also be highlighted that the concept of comorbidity can be difficult to define.
Accordingly, a relevant review by Valderas et al. [26] draws attention to the fact that the
concept of comorbidity might overlap with other related constructs, such as the burden
of disease and multi-morbidity, further suggesting that there are a number of distinctions
pertaining to this concept. For example, it is important to consider the nature of the
condition and the basis for classification, as certain conditions may form part of a spectrum
rather than existing as separate entities. The importance of the condition also represents
a key factor in terms of ascertaining which disorder might represent the core or ‘index’
disorder, and which might be referred to as the ‘comorbid’ condition when two or more
conditions co-exist.
Taking into account the above, the present review examined published research that
indicates the presence of associations between NAFLD and highly prevalent mental health
disorders, namely depression, anxiety, and chronic stress, as well as impaired HRQoL,
which is closely linked to mental health wellbeing. The aim of this review is to provide a
comprehensive overview of the current evidence on the potential relationship(s) between
these common mental health problems and both NAFLD and metabolic syndrome, keeping
in mind the complexity of the concept of comorbidity. Thus, this review will begin by
discussing current evidence in relation to depression, anxiety, and chronic psychosocial
stress within the context of associations with metabolic syndrome and NAFLD. Then,
associations between impaired HRQoL and both the metabolic syndrome and NAFLD
are also summarized. Finally, the concluding sections of this review also focus on key
underlying mechanisms that are considered to mediate associations between NAFLD,
metabolic syndrome, and mental health, as well as on the gaps/weaknesses of the relevant
published literature, and the future research directions which need to be further explored.
The main studies included in this review are summarized in Tables 1 and 2.
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2. Methods
Although this work presents a narrative review, rather than a systematic review, a
predefined search strategy was formulated and was applied to identify relevant papers in
the English language, utilizing both relevant search terms and medical subject headings
(MeSH) [27], which related to NAFLD, metabolic syndrome, depression, anxiety, stress,
and HRQoL. The searched databases included both PubMed and Google Scholar, focusing
predominantly on work published over the past decade. After removing duplicates and
screening, key papers that reported evidence on identified associations between NAFLD or
metabolic syndrome and depression, anxiety, stress, and HRQoL were reviewed in full and
were included as relevant to the scope of this review, as presented in the following sections.
3. Depression
Often accompanied by rumination and cognitive impairment, depression is a highly
prevalent illness, which affects more than a quarter of a billion people of all ages and
constitutes a leading cause of years lived with disability globally [14,28,29].
3.1. Depression/Anxiety and Metabolic Syndrome
It is now recognized that depression and/or anxiety are associated with increased
risk of CVD and metabolic syndrome components (e.g., depression exhibits an indepen-
dent association to 10-year CVD incidence, and increases the risk of T2DM by up to
60%) [21,30,31]. Links between depression/anxiety and increased likelihood of alcohol
overconsumption and poor dietary and/or exercise habits are considered among the pos-
sible mediators of these associations [32]. This is further supported by systematic review
data showing that affective disorders, such as depression, can double the risk of metabolic
syndrome, partially owing to the poor health-related behaviors associated with depres-
sion [14]. Although significant associations between depression and metabolic syndrome
are supported by such data, a potential causal bidirectional relationship remains to be
fully elucidated, as depression may promote metabolic syndrome, while factors related to
metabolic syndrome—either psychological (e.g., obesity-related stigma) or biological (e.g.,
increased activation of pro-inflammatory pathways representative of the stress response
system)—may also lead to depression [14,23].
Furthermore, various studies have demonstrated positive associations between metabolic
syndrome and anxiety, indicating that, in addition to depression, anxiety may also be
significantly more prevalent in individuals with metabolic syndrome compared with
those without [33,34]. This significant association of anxiety with metabolic syndrome
is also supported by systematic review and meta-analysis data, which pooled findings
from 18 relevant cross-sectional studies [35]. However, other comorbidities and their
related symptoms may overlap with symptoms included in tools designed to measure
depression and anxiety. Indeed, some earlier studies have been unable to detect significant
associations between metabolic syndrome and anxiety [36,37]. Likewise, in the two cohort
studies included in the systematic review by Tang, Wang, and Lian [35], no significant
association was found between anxiety and metabolic syndrome [38,39]. Interestingly, a
cross-sectional study by Akbari et al. [40], utilizing a sample from the Isfahan Cohort Study
in Iran, reported a negative relationship between anxiety and metabolic syndrome, with
a lower prevalence of metabolic syndrome in patients with anxiety compared with those
without. This finding contradicts the reported outcomes of the aforementioned studies,
and may be potentially attributed to the applied methodology, with the study authors
drawing attention to the use of a self-reported tool for measuring anxiety and depression
(i.e., the hospital anxiety and depression scale, HADS), rather than the application of more
rigid diagnostic methods.
3.2. Depression/Anxiety and NAFLD
Given the identified relationships between affective disorders and metabolic syn-
drome, it is plausible that similar positive associations may exist between such mental
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health conditions and NAFLD. However, Weinstein et al. [41] report that, despite the recog-
nition that depression is associated with many medical conditions, much less attention has
been directed towards patients with chronic liver disease. With this in mind, these authors
conducted a study aimed at comparing the prevalence of depression in individuals with
NAFLD, hepatitis B, and hepatitis C, utilizing data extracted from a database containing
clinical and self-reported depression data for CLD patients. This study identified a higher
prevalence of depression in patients with NAFLD and hepatitis C, compared with patients
with hepatitis B and members of the general population.
In a study by Youssef et al. [42], the potential association between depression/anxiety
and the histological features of NAFLD among 567 patients diagnosed with NAFLD was
explored. Subclinical depression was identified in 53% of these patients, while clinical
depression was observed in 14%. Similarly, subclinical and clinical anxiety was observed
in 45% and 25% of these patients, respectively. Notably, this study identified a positive
association between greater hepatocyte ballooning and depression in patients with NAFLD.
Although the exact underlying mechanisms for this association remain unclear, it is note-
worthy that the clinical and lifestyle variables measured in this study, including body mass
index (BMI) and hypertension, were associated with the severity of both depression and
anxiety [42]. Another interesting study by Jung et al. [43], involving a Korean population,
further sought to investigate the extent to which the risk for depression might be associated
with the severity of NAFLD. Indeed, evidence of an association between the severity of
NAFLD and depression emerged from this study, leading the authors to suggest that
advanced stages of NAFLD potentially have a greater association with depression [43].
Similarly, a recent retrospective cross-sectional study by Choi et al. [44] identified that se-
vere steatosis is significantly related to both state and trait anxiety in patients with NAFLD.
However, this study did not observe associations between NAFLD and depression until
gender was taken into consideration, whereby a 44% increase in the risk of depression
among women with NAFLD was demonstrated.
In a small cohort study conducted in Pakistan, the frequency of depression, as assessed
by the Patient Health Questionnaire (PHQ-9), in 170 patients with ultrasound-diagnosed
NAFLD was investigated [45]. Almost one in four participants of this study were identified
as having depression, with no significant impact of gender, age, or socioeconomic status on
depression in these NAFLD patients. Despite the small sample size, this study suggests that
depression appears more frequently in individuals with NAFLD, highlighting the need for
further research in this field. Indeed, using data from a large sample of 10,484 individuals
in the United States, Kim et al. [46] also identified a higher prevalence of depression among
individuals with NAFLD compared with those without. This study further revealed that
subjects with depression were at a higher risk of developing NAFLD. Although individuals
with depression were of older age and had other comorbidities, such as diabetes and
hypertension, as well as higher total cholesterol and BMI, the findings of this study indicate
that depression may represent an independent risk factor in relation to NAFLD [46].
Moreover, the longitudinal association between depression and the risk of NAFLD
was examined by Cho et al. [47] in a cohort of 142,005 Korean adults without excessive alco-
hol consumption or hepatic steatosis at baseline that were followed for up to 8.9 years [47].
The findings of this study showed that depression at baseline, as assessed by the vali-
dated Center for Epidemiologic Studies-Depression score (CES-D), was associated with
an increased risk of incident hepatic steatosis diagnosed by ultrasonography, as well as a
higher probability of advanced liver fibrosis, particularly among individuals with obesity.
In another large study involving a sample of 19,871 patients with NAFLD and a matched
control group of 19,871 individuals, Labenz et al. [48] investigated associations between
NAFLD and depression and anxiety over the course of a 10-year period. Over this study
timeframe, the percentage of individuals diagnosed with depression was 21.2% and 18.2%
for those with and without NAFLD, respectively, while the corresponding anxiety rates
were 7.9% and 6.5%, respectively. Furthermore, this study identified a significant associa-
tion between NAFLD and an initial antidepressant prescription [48]. Although this study
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was unable to prove causality, a significant association between NAFLD and development
of depression/anxiety was noted, independent of comorbidities.
A further important point for the clinical practice is that depressive disorders may also
have an impact on the treatment outcomes in patients with NAFLD. This was evident in a
study by Tomeno et al. [25], which explored the effects of a 48-week lifestyle intervention
in patients with NAFLD presenting with or without major depressive disorder (MDD). Of
the 258 patients participating in this study, 32 presented with MDD in addition to NAFLD,
and these patients exhibited a poor response with less effective treatment outcomes. The
poor adherence/outcomes noted in this study could be due to psychological factors related
to depression, including effects on memory and self-efficacy [25]. This suggests that multi-
component lifestyle modification programmes may be required in patients presenting with
both NAFLD and MDD [25].
Overall, depression has been identified as one of the most common extrahepatic dis-
eases associated with NAFLD [49] and, collectively, the aforementioned evidence suggests
a potential bidirectional association of depression and anxiety with the development, and
even the severity, of NAFLD. However, other underlying factors may be either media-
tors or confounders in these associations, including the well-established links between
depression/anxiety and unhealthy lifestyle behaviors, and the co-existence of other cardio-
metabolic comorbidities. Indeed, a recent systematic review and meta-analysis highlights
several risk factors (including BMI, diabetes, and being female) associated with a high
prevalence of depression in NAFLD patients [50]. Therefore, it remains unclear whether
depression and/or anxiety can be considered independent risk factors for the development
and progression of NAFLD, and vice versa. Thus, the existing evidence warrants further
investigations aiming to clarify the extent and direction(s) of the potential associations
between depression/anxiety and NAFLD.
4. Chronic Psychosocial Stress
The concept of stress has been linked with physical health conditions for a considerable
time, because, as reported by Selye, we have had some notion of the concept of stress
ever since the word ‘disease’ was first used [51]. To date, psychosocial stress is known to
be associated with increased prevalence rates of a number of cardio-metabolic diseases,
including obesity, T2DM, hypertension and CVD [23,52]. Of note, chronic psychosocial
stress poses a risk factor for obesity, with evidence suggesting that this might be reflective
of exposure to a wide range of different stressors rather than resulting from a single
stressor [23,53].
4.1. Chronic Psychosocial Stress and Metabolic Syndrome
Chronic psychosocial stress has frequently been reported as a risk factor for metabolic
syndrome, partially associated with disturbances in metabolic homeostasis [21–23,54–56].
Therefore, the cardio-metabolic effects of chronic psychosocial stress in the longer term can
be highly damaging [23,31].
In a systematic review, Kuo et al. [57] sought to further establish whether the as-
sociation between stress and metabolic syndrome differed depending on the source of
stress. The meta-analysis of the available data showed that the weakest effect was noted for
general stress, while the strongest effect was evident for occupational stress. These authors
concluded that research should investigate the impact of frequently experienced different
sources of stress on metabolic consequences, and suggested that the usual methods for
the prevention of metabolic syndrome, such as lifestyle changes, may be less effective if
psychosocial stress is overlooked [57].
4.2. Chronic Psychosocial Stress and NAFLD
Limited research studies have explored relationships between stress and NAFLD,
although an underlying association is considered likely [56]. Indeed, stress involves both
behavioral and biological responses, which activate the hypothalamic–pituitary–adrenal
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(HPA) axis, resulting in elevated levels of cortisol and pro-inflammatory biomarkers that
could be involved in the development of NAFLD [56].
Notably, in exploring correlations between NAFLD, dietary habits, stress, and HRQoL
in Korean individuals, Han [58] identified a 1.3-fold increase in the risk of NAFLD in
individuals with increased perceived stress, suggesting that stress management should
be included in the treatment of NAFLD [58]. Furthermore, a large cross-sectional study
involving 171,321 apparently healthy Korean adults identified an independent association
between higher levels of perceived stress and a higher prevalence of NAFLD [56]. This
association was stronger among men and individuals with obesity in comparison with
women and those with normal body weight, while it remained significant after adjusting
for multiple metabolic, behavioral and socioeconomic factors. Indeed, although stress
is often linked to unhealthy behaviors, the noted association was still significant even
after controlling for such risk factors (e.g., smoking, lack of physical activity, and alcohol
consumption), highlighting that further research is needed to fully ascertain the potential
mediating mechanisms [56].
In addition, meta-analysis data from 16 prospective studies in the U.K. general pop-
ulation with 166,631 individuals and a follow-up period of approximately 9.5 years [9]
showed that psychological distress was associated with significantly increased liver disease
mortality, together with increased scores on the 12-item version of the General Health
Questionnaire (GHQ-12). Given that psychological distress is a risk factor for CVD [59,60],
these findings suggest that it could also play a role in the development of liver disease. Fur-
thermore, because the association between liver disease and psychological distress could
not be totally explained by lifestyle habits, BMI, socioeconomic status, or the co-existence
of diabetes, this study concluded that other underlying mechanisms might be also partially
responsible for this link [9].
In view of the evidence suggesting that both occupational stress and NAFLD represent
growing public health issues, Li et al. [61] sought to identify relationships between these
two conditions in a population of Chinese police officers. Among these participants,
moderate and high occupational stress, as well as high personal strain, were identified
as independent risk factors for NAFLD, compared with low occupational stress and low
personal strain, which appeared to play a protective role. Of interest, the presence of
NAFLD was significantly higher in traffic police officers compared with other members
of the police force, drawing attention to the fact that these traffic police officers encounter
occupational exposure to traffic noise and air pollution on a full-time basis on most days.
As such, this study further suggested that environmental factors may also be implicated in
the relationship between NAFLD and occupational stress [61].
Although research in this field remains limited, the aforementioned studies, as well as
evidence from animal studies [62], support the existence of direct links between chronic
psychological stress and NAFLD. As such, while further research is clearly needed, this
evidence suggests that NAFLD may represent a stress-sensitive disorder for which stress
management interventions could be beneficial.
5. Health Related Quality of Life (HRQoL)
Both physical and mental health problems may have a significant impact on HRQoL.
Thus, the assessment of self-reported quality of life can be of significant clinical value in the
management of chronic disorders, in order to address both the psychosocial and physical
needs of patients [63].
5.1. HRQoL and Metabolic Syndrome
Emerging data from a growing number of studies have indicated decreased HRQoL
in patients with metabolic syndrome [64–66]. For example, when assessing metabolic syn-
drome as a determinant of HRQoL, a cross-sectional study conducted in Greece identified
impaired HRQoL on almost all subscales of the validated Greek version of the 36-item Short
Form Survey questionnaire (SF-36) for patients with metabolic syndrome compared with
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controls [66]. Likewise, an earlier U.S. study identified reduced HRQoL in individuals with
metabolic syndrome compared with those without [64]. In contrast, research from Korea
suggests a lack of an independent relation to impaired HRQoL in people with metabolic
syndrome after adjusting for various confounding variables (e.g., multiple comorbidities),
suggesting that the presence of comorbidities may account for the decreased HRQoL
among metabolic syndrome patients [67]. However, the findings from a recent systematic
review of 30 relevant studies involving 62,063 adults with metabolic syndrome provide
further evidence of the positive association between metabolic syndrome and impaired
HRQoL [65].
5.2. HRQoL and NAFLD
Although data are relatively limited with regard to NAFLD and HRQoL, a number of
studies have investigated such a potential relationship. The 29-item Chronic Liver Disease
Questionnaire (CLDQ) was utilized in many of these studies, as a disease-specific tool
designed to measure HRQoL in individuals with chronic liver disease [68,69]. Indeed,
Dan et al. [70] compared HRQoL, as assessed by the CLDQ, in patients with NAFLD
and those with chronic hepatitis B or chronic hepatitis C, revealing significantly worse
HRQoL in the former for both the overall CLDQ score and most of its subscales [70].
Notably, although a large proportion of NAFLD patients in this study also presented with
hypertension, diabetes, and metabolic syndrome, the impact on HRQoL did not appear to
be completely explained by these comorbidities [70].
The CLDQ was also utilized in a prospective United States-based study by Tapper and
Lai [71] involving 151 adults with a histologic diagnosis of NAFLD [71]. This study, which
was designed to investigate whether HRQoL could be improved by a lifestyle-modification
intervention (exercise programme along with dietary recommendations for weight loss),
revealed that patients with a 5% weight reduction at the 6-month follow-up showed
significantly improved HRQoL [71]. Likewise, a recent study by Castellanos-Fernández
et al. [72], which incorporated the CLDQ to assess HRQoL among Cuban patients with
NAFLD, autoimmune liver diseases, and hepatitis B, documented significantly lower
HRQoL for patients with NAFLD and autoimmune liver diseases compared with those
with hepatitis B. Interestingly, sleep apnea and abdominal pain were more frequently
identified in patients with NAFLD, which may have contributed to reductions in HRQoL
among this patient group [72].
Utilizing data from the National Health and Nutrition Examination Survey (NHANES),
Golabi et al. [73] assessed HRQoL in 3333 patients with NAFLD compared with 5982
healthy controls. This study invited participants to rate four components of HRQoL over
the previous 30-day period and included questions in relation to perceived health status
(overall HRQoL), the number of days experienced with physical illness and injury, the
number of days within which mental health issues were encountered, and the extent to
which physical or mental health had prevented the participant from engaging in usual
activities [73]. Notably, participants in the study control group rated their health status as
significantly higher than those in the NAFLD group, and were more likely to report an
absence of physical health problems. Furthermore, the control group reported significantly
fewer occasions whereby physical or mental health issues had prevented engagement in
usual activities, indicating that the poorer health status of NAFLD patients may affect their
ability to perform normal daily activities. However, it was also suggested that fatigue
could have had an impact on the poorer reports of physical health in patients with NAFLD,
as this symptom was frequently present among NAFLD patients [73].
Another recent study, which explored the relationship between NAFLD and dietary
habits, stress, and HRQoL, reported reduced HRQoL in Korean adults with NAFLD [58].
In this study, HRQoL was assessed by the EuroQol-5D (EQ-5D) instrument, which mea-
sures/comprises of five dimensions, namely, mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression. This study showed that a decrease in the EQ-5D score
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by one unit was associated with increased risk of NAFLD by more than threefold, raising
the awareness of considering HRQoL in the context of NAFLD [58].
Overall, systematic review data from 14 relevant studies collectively suggest that
NAFLD patients have poorer HRQoL in comparison with healthy controls [63]. It is clear
that further work is needed in order to address the direct impact of NAFLD on HRQoL,
and to gain a further understanding of the underlying mediating factors. Investigating
potential predictors of HRQoL in NAFLD patients (e.g., obesity and obstructive sleep
apnea), and the extent to which other related comorbidities (e.g., fatigue, depression, and
anxiety) may impact the HRQoL could be of clinical importance.
6. Potential Underlying Mechanisms Linking NAFLD with Depression, Anxiety,
and Stress
A growing burden of disease due to mental health disorders and increasing trends of
somatic-psychiatric comorbidity have been noted globally, while patients presenting with
multiple diseases are frequently the rule rather than the exception [74,75]. Coexistence
of two or more health conditions may be explained by a number of factors, including
coincidence without underlying causal connection(s) [74–76]. Indeed, surveillance bias
may partly explain the fact that patients already receiving care for one chronic disease are
more likely to be diagnosed with one or more additional health conditions [76]. However,
comorbidity often occurs as a result of true underlying pathophysiologic mechanisms,
which may represent direct causal link(s) and/or common risk factor(s) [74–76]. An indirect
link may also be present between coexisting health conditions, when these have direct
causal connection(s) with another common disease/condition [76].
As is now well-established for the clustering of cardio-metabolic conditions within
the spectrum of the metabolic syndrome [10], the existing evidence indicates that the
direct positive associations between mental health disorders (e.g., depression, anxiety,
and chronic stress), and both NAFLD and the metabolic syndrome may be attributed to
true pathophysiologic links rather than just coincidence [23]. In this context, multiple
underlying mechanisms have been proposed to play a role in mediating these associations.
The most salient of these potential mechanisms are briefly outlined in this section, while
Figure 1 presents these in a simplified schematic diagram.
It is also noteworthy that gender variations in relationship to stress, mental health, and
metabolic diseases pose a further issue, since men and women may differ in terms of preva-
lence and response to these conditions. Indeed, as reported in a study by Choi et al. [44],
NAFLD occurs more commonly in men, while depression was almost two times more
prevalent in women compared with men. It is further reported that, although disorders
such as CVD may be seen as more common in men, certain modifiable risk factors for
obesity, metabolic disease, and CVD (e.g., stress) are higher in women [77]. Interestingly,
attention has also been drawn to findings that indicate that responses to stress may in
fact be similar in men and women, while engaging distinct neural networks [78]. Finally,
potential differences between men and women in relevant health behaviors and in the
regulation of glucose and energy homeostasis have also been reported [79,80].
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as on the individual’s predisposition, one or more vicious cycles may develop over time linking 
MAFLD and related cardio-metabolic diseases (e.g., central obesity and metabolic syndrome) with 
mental health comorbidity. Hypothalamic–pituitary–adrenal (HPA) axis dysregulation, pro-inflam-
matory processes, insulin resistance, and unhealthy lifestyle behaviors (e.g., unhealthy diet and sed-
entary lifestyle) are among the key mechanisms mediating such potentially bidirectional associa-
tions and feed-forward vicious cycles. 
6.1. Chronic Stress and HPA Axis Dysregulation 
Bergmann, Gyntelberg, and Faber [55] suggest that stress can be understood by its 
division into three components, namely, stressors, the body’s reaction to stressors, and the 
emotional effects of such reactions. Once the threshold of an individual is exceeded by the 
sum of applied stressors, the stress response is activated via the HPA axis and the sympa-
thetic nervous system (SNS). Prolongation of this stress response can progressively lead 
to HPA dysregulation and depression, which could result in subsequent physical illness 
[32]. Indeed, chronic stress can cause hyper-activation of the HPA axis and the SNS, 
which, in turn, is associated with obesity (particularly abdominal/central) and metabolic 
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6.1. Chronic Stress and HPA Axis Dysregulation
Bergmann, Gyntelberg, and Faber [55] suggest that stress can be understood by its
division into three components, namely, stressors, the body’s reaction to stressors, and
the emotional effects of such reactions. Once the threshold of an individual is exceeded
by the sum of applied stressors, the stress response is activated via the HPA axis and the
sympathetic nervous system (SNS). Prolongation of this stress response can progressively
lead to HPA dysregulation and depression, which could result in subsequent physical
illness [32]. Indeed, chronic stress can cause hyper-activation of the HPA axis and the SNS,
which, in turn, is associated with obesity (particularly abdominal/central) and metabolic
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syndrome [23]. Although a number of factors may determine how an individual adapts
and responds to stressful situations, the HPA axis represents the major neuroendocrine
system responsible for stress regulation via a process regulating the appropriate and timely
release of glucocorticoids. This process crucially involves a negative feedback loop, which
is of paramount importance in regulating the individual’s response to stress, as it prevents
cortisol over-production/secretion. If this inhibitory procedure fails to operate efficiently—
for example, under conditions of chronic stress—inappropriate and/or high secretion of
cortisol by the adrenals can promote the development of the various metabolic syndrome
manifestations, including NAFLD [23]. Of note, cortisol/glucocorticoids increase hepatic
gluconeogenesis and blood glucose levels and promote visceral/central fat accumulation,
while simultaneously inducing lipolysis (e.g., in subcutaneous adipose tissue depots) and
protein degradation (e.g., in skeletal muscle) to provide additional substrates for oxidative
pathways in response to stress [23]. These cortisol-induced effects normally stop in a
prompt manner upon the removal of the stressor(s), which caused the HPA axis activation.
However, chronic stress and over-activation of the HPA axis prolong these metabolically
detrimental effects, and can progressively result in increased visceral/central adiposity,
insulin resistance, and ectopic accumulation of fat in the liver, all of which are factors
contributing to the development and progression of NAFLD [10,23].
6.2. Obesity-Related Inflammation and Insulin Resistance
Obesity is associated with, and may lead to, a range of cardio-metabolic, including
T2DM, NAFLD and CVD, as well as mental health comorbidities [10]. In this setting, a
cyclical relationship with bidirectional links between obesity and psychological health
appears plausible, with affective disorders and chronic stress representing risk factors for
obesity, and vice versa [10]. Indeed, HPA axis dysfunction resulting from exposure to
prolonged stress can result in adipose tissue accumulation leading to obesity, while obesity
in itself is a chronic stressful condition that might lead to HPA axis over-activation (e.g., as
a consequence of obesity-related chronic inflammatory stress) [22]. This can further lead to
increased risk for metabolic syndrome, NAFLD, and CVD [10,22].
To date, a number of studies have identified associations between circulating C-
reactive protein (CRP) levels and depression in individuals with obesity [81,82], suggesting
that obesity-related pro-inflammatory pathways may play a mediating role in the un-
derlying pathophysiology linking these diseases, including NAFLD. Notably, metabolic
syndrome and MDD—which as aforementioned frequently coexist—have been also consis-
tently associated with chronic low-grade inflammation with increased circulating levels
of multiple pro-inflammatory factors [13]. There is also evidence for a bidirectional link,
whereby an unhealthy lifestyle as a result of depression may increase inflammation, leading
to a feed-forward vicious cycle [23,59].
It is further reported that HPA axis dysregulation as a result of negative emotions
in response to chronic and/or intense stress could lead to the onset of NAFLD owing
to activated hepatic pro-inflammatory processes [9,62]. A study by Russ et al. [9] in-
dicated that inflammation is frequently a prominent feature of NAFLD, which denotes
progression to non-alcoholic steatohepatitis (NASH), with a strong identified relationship
between NAFLD and psychological stress. Thus, it would appear that pro-inflammatory
factors related to psychological distress are also mediators in an important pathway be-
tween psychosocial stress and NAFLD [9,13]. Indeed, bidirectional relationships have
also been suggested between psychiatric disorders and other chronic immune-mediated
inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, ulcerative colitis
and Crohn’s disease) [76]. Pro-inflammatory pathways, immune dysregulation, and sys-
temic or multi-organ inflammation are considered to mediate these bidirectional links [76],
and these may similarly contribute, at least in part, to the common pathophysiology be-
tween certain mental health disorders (e.g., depression, anxiety, and chronic stress) and
NAFLD/NASH [10,23].
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As well as systemic low-grade inflammation, insulin resistance has been implicated
as a potential causal mechanism linking metabolic dysregulation with depressive disor-
ders [83]. As aforementioned, insulin resistance is also included among the detrimen-
tal effects of HPA dysfunction, mediated mostly via over-secretion of cortisol by the
adrenals and of adipokines/cytokines by the accumulated excess and/or ectopic adipose
tissue [10,13,23]. Overall, there appears to be an interaction between insulin resistance,
psychological health, and NAFLD [58]. Interestingly, in testing the hypothesis that insulin
resistance or inflammation might partially explain the relationship between depression
and NAFLD, Lee et al. [84] were unable to identify such a link when utilizing CRP as a
biomarker. However, a 40–50% increased risk of NAFLD in individuals with depression
was identified in this study, whereby depression appeared to be linked to insulin resis-
tance (rather than to inflammation), suggesting that insulin resistance may be driving the
increased risk for NAFLD.
6.3. Gut Microbiome Dysbiosis in Metabolic Diseases and Its Association with
Psychological Disorders
Bacteria within the gut are now recognised to play a major role in the bi-directional
communication between the gastrointestinal tract and the brain, which seems to be me-
diated via intricate mechanisms and pathways [85,86]. This is supported by a growing
body of emerging data indicating that the gut microbiome plays an important role in both
physical and mental health through a number of bi-directional processes and appears to be
associated with a number of conditions, including neuro-psychiatric, psychological, and
physiological disorders [85]. Of note, lifestyle factors affect the maintenance of the normal
gut microbiota, with diet being of particular importance, as is evident from both animal and
human studies [85]. Indeed, the gut microbiome is influenced by dietary factors, such as
low fibre intake, which can result in dysbiosis and inflammatory processes that may impact
both mental and physical health [85]. In this context, the dysbiosis of the gut microbiota is
shown to have a number of effects on metabolism, which can affect the body weight [87].
For example, Westernised dietary habits are implicated in the pathogenesis of obesity and
may lead to an imbalance in gut microbiota, which can further contribute to obesity-related
complications via a number of processes, including endocrine, neurochemical, and inflam-
matory alterations [88]. As such, it appears that gut microbiota may also be implicated in
the aetiology of NAFLD, particularly as certain microbiota enterotypes appear to exhibit a
greater ability to absorb energy from the diet and seem to be linked to higher total body
fat [89]. Finally, there are also established relationships between obesity and mental health
that may be connected to changes in gut microbiota, resulting in such a comorbidity [88].
Accordingly, the gut microbiome dysbiosis in obesity-related cardio-metabolic diseases
may be further implicated in the pathophysiology between NAFLD and mental health
disorders, such as depression, anxiety and chronic stress, and dietary changes, which
can address this dysbiosis may potentially lead to improvements in both physical and
psychological health.
7. Future Research Directions and Concluding Remarks
NAFLD has strong associations with metabolic syndrome and represents a growing
and important public health issue globally. The studies outlined in this review, and sum-
marized in Tables 1 and 2, link NAFLD—directly or indirectly (via a strong overlap with
the metabolic syndrome)—with prevalent mental health problems, such as depression,
anxiety, and chronic stress, thus expanding the spectrum of its potential pathophysiologic
associations. Indeed, the relevant existing evidence indicates that further aspects relating to
mental health and HRQoL may have clinical implications for the management of patients
with NAFLD, and hence are worthy of more thorough investigations. However, there
are certain difficulties associated with such work owing both to the complex nature of
affective disorders, and to the substantial overlap of NAFLD with multiple other conditions
related to obesity and the metabolic syndrome. For example, there are different types of
depression (e.g., MDD and bipolar) and anxiety (e.g., general, social, panic disorder, and
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phobias) that increase the complexity of the relevant diagnoses and management [90–93].
In addition, there are a number of validated tools for assessing depression and anxiety in
primary care settings, with the PHQ-9 and GAD-7 proving particularly popular [94–96],
but practical issues (e.g., time constraints) could also contribute to the under-detection of
such conditions. Likewise, stress can be broken down into a range of different types repre-
senting a complex impact (e.g., physical or psychosocial stress, as well as post-traumatic,
occupational/workplace, or financial stress) [90,97]. Interestingly, studies involving animal
models have provided evidence that changes in behavior may differ depending on the
type of stress experienced [98]. Again, there are various tools for measuring stress, with
the Perceived Stress Scale being particularly widely used [99]. Therefore, it should also
be highlighted that, although almost all of the studies presented in this review utilized
validated instruments for assessing mental health comorbidity (depression, anxiety and
stress), these self-reported measures may not fully capture the details required for pre-
cise diagnosis and/or severity assessment of the corresponding underlying condition(s).
Hence, it is suggested that relevant future studies should also incorporate structured di-
agnostic methods for the precise assessment of mental health comorbidity, in addition to
participant-reported measures [40,84].
Additionally, it is important to consider the issue of multi-morbidity and overlapping
symptoms. Certain studies indicate a potential independent association between mental
health and NAFLD [46,70], while others report on the presence of sleep disorders and
fatigue in NAFLD patients, which might have an impact on responses to self-report
measures related to mental health [72,73]. Furthermore, most of the existing studies
in this field utilized cross-sectional research designs, which, although useful for identifying
associations, are unable to provide information regarding causality. As such, given the
relationship with other comorbidities and the difficulties in determining causality, future
studies employing a longitudinal design may prove fruitful in attempting to overcome this
issue [44].
Of further note, as weight gain is implicated in the progression of insulin resistance and
NAFLD, consideration should be given to the potential weight gain side effects of certain
medications for mental health disorders (e.g., certain antidepressants) [10,89]. Indeed, a
review by Hasnain and Vieweg [100] highlights the weight changing effects of certain
medications used to treat a number of mental health conditions (e.g., mood stabilizers,
antidepressants, and anti-anxiety medications), and draws attention to the potential benefits
of switching such medications in situations whereby weight gain becomes troublesome,
taking into consideration both the patient’s condition and possible side effects. Notably,
a recent systematic review suggests that metabolic disorders are often exacerbated in
people taking antidepressant or antipsychotic medications, with most of the reviewed
studies showing a 5% weight gain in individuals under antidepressant therapy [101].
Considering such data, and given the frequency with which antidepressants are currently
prescribed, it becomes evident that, although the weight gain risk may be slightly lower
with antidepressants compared with antipsychotic drugs [102,103], it is important to also
consider the potential weight gain adverse effects of drugs prescribed for mental health
conditions, particularly when investigating associations between mental health and obesity-
related cardio-metabolic disorders, such as NAFLD.
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Table 1. Selected studies on links between metabolic syndrome and mental health wellbeing.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed and Method Outcome/Main Findings










Supports a significant relationship between
anxiety and metabolic syndrome.




N = 470 (male: 50.2%)
Mean Age: 55.7 ys
Depression/Anxiety
HADS
No significant association between depression,
concurrent depression, and anxiety with
metabolic syndrome.
Patients with anxiety had lower prevalence of
metabolic syndrome than healthy subjects.




N = 384 (female: 53.6%)
Mean Age: 63.7 ys
Without Metabolic Syndrome:
N = 731 (male: 52.5%)




Depression and anxiety was identified as being
more common in individuals with metabolic
syndrome in comparison with those without.
Dunbar et al. (2008)
[35] Australia
Cross-Sectional
N = 409 (male: 50.9%)




Results show an association between metabolic
syndrome and depression, but not with
psychological distress and anxiety.
Shinkov et al. (2018)
[33] Bulgaria
Cross-sectional
N = 2111 (female: 54.7%)
Mean Age: 46.4 ys
Depression/Anxiety
Zung Self-Rating Depression and
Anxiety Scales
Depression and anxiety scores were higher for
those with metabolic syndrome.
Skilton Moulin et al. (2007)
[36] France
Observational
N = 1598 (male: 62.9%)
Mean Age: 51.8 ys
Depression/Anxiety
HADS
Metabolic syndrome was associated with
depressive symptoms, but not with anxiety in
men and women, irrespective of body weight.








Different sources of frequently occurring stress
should be investigated.
Usual methods (e.g., lifestyle change) for
preventing metabolic syndrome, may be less
effective if psychosocial stress is overlooked.
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Table 1. Cont.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed and Method Outcome/Main Findings




N = 737 (female: 50.4%)
Mean Age: 52.2 ys
Without metabolic syndrome:
N = 1122 (female: 50.5%)
Mean Age: 41.8 ys
HRQoL
Centers for Disease Control and
Prevention HRQOL-4 tool
HRQoL was worse in people with metabolic
syndrome compared with those without.




N = 2635 (male: 56%)
Mean Age: 52.8 ys
Without Metabolic Syndrome:
N = 6306 (male: 52.3%)




Unable to identify and independent association
in relation to impaired HRQoL in people with
metabolic syndrome after adjusting for
confounding variables.






SF-36 was the most frequently
utilized
Evidence suggests association between
metabolic syndrome and poorer HRQoL.




N = 206 (female: 54.8%)
Mean Age: 58.4 ys
Controls:
N = 153 (male: 53%)
Mean Age: 50.1 ys
HRQoL
SF-36
Study identified impaired HRQoL on almost all
subscales of the SF-36 for patients with
metabolic syndrome compared to controls.
EQ-5D: EuroQoL 5 dimensions; EQ VAS: EuroQol visual analogue scale; HADS: Hospital Anxiety and Depression Scale; HRQOL: Health-Related Quality of Life; MINI: Mini International Neuropsychiatric
Interview; PHQ-9: Patient Health Questionnaire; SF-36: Short Form-36; ys: years.
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Table 2. Selected studies on links between non-alcoholic fatty liver disease (NAFLD) and mental health comorbidity.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed & Method Outcome/Main Findings




N = 170 (male: 64.1%)
Mean Age: 39.8 ys
Depression
PHQ-9
24.1% of NAFLD patients suffered from clinical
depression, implying frequency of depression in
people with NAFLD.
Cho et al. (2021)
[46] Korea
Longitudinal
N = 142,005 (female: 64.6%)
Mean Age: 35.6 ys
Depression
CES-D
Depression was associated with increased risk of
incident hepatic steatosis and higher probability of
advanced liver fibrosis, particularly among
individuals with obesity.
Jung et al. (2019)
[42] Korea
Observational
N = 112,797 (female: 51.5%)
Mean Age: 40 ys




Evidence of an association between the severity of
NAFLD and depression.
Kim et al. (2019)
[45] USA
Cross-sectional
N = 10,484 (female: 51.2%)
Mean Age: 47 ys
NAFLD defined by USFLI, HSI, and FLI
Depression
PHQ-9
Study identified a higher prevalence of depression
among individuals with NAFLD compared to
those without.
Sayiner et al. (2020)
[48] USA
N = 30,908,679 (random 5% sample of




Based on ICD-9 and ICD-10 codes
Depression identified as one of the most common
extrahepatic diseases associated with NAFLD.




NAFLD comorbid with MDD:
N = 32 (male: 56.2%)
Mean Age: 46.5 ys
NAFLD without MDD:
N = 226 (male: 52.6%)
Mean Age: 50.7 ys
NAFLD diagnosis based on liver biopsy
Depression
MDD diagnosed according to the
DSM-IV criteria.
Following a 48-week lifestyle intervention, patients
with NAFLD demonstrated a poor response with
less effective treatment outcomes.
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Table 2. Cont.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed & Method Outcome/Main Findings




N = 184 (female: 69.4%)
Mean Age: 46.7 ys
Hepatitis B:
N = 190 (male: 61.9%)
Mean Age: 43.6 ys
Hepatitis C:
N = 504 (male: 59.7%)
Mean Age: 48.6 ys
Depression
Self-reported
Diagnosis confirmed by history of
prescription medication.
Study identified a higher prevalence of depression
in patients with NAFLD and HCV, compared with
patients with HBV and members of the
general population.
Xiao et al. (2021)
[49] Singapore





High prevalence of depression in NAFLD patients
was identified.
Risk factors include BMI, diabetes, and
being female.
Choi et al. (2021)
[43] South Korea
Retrospective Cross-Sectional
N = 25,333 (male: 56.2%)






Severe steatosis is significantly related to both state
and trait anxiety in patients with NAFLD. When
gender was taken into consideration, a 44%
increase in the risk of depression among women
with NAFLD was demonstrated.




N = 19,871 (male: 57.5%)
Mean Age: 58.5 ys
Patients without NAFLD:




Study highlighted a significant association between
NAFLD and development of depression/anxiety
was noted, independent of comorbidities.
Youssef et al. (2013)
[41] USA
Cross-sectional
N = 567 (female: 67%)
Mean Age: 48 ys
NAFLD diagnosis based on liver biopsy
Depression/Anxiety
HADS
Symptoms of depression and anxiety common in
patients with NAFLD.
Study identified a positive association between
greater hepatocyte ballooning and depression in
patients with NAFLD.
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Table 2. Cont.





N = 17,726 (male: 50.6%)
Mean Age: 43.9 ys
HSI ≥ 36:
N = 3764 (male: 61.3%)
Mean Age: 45.1 ys
HSI < 36:
N = 13,962 (female: 52.5%)
Mean Age: 43.5 ys





Decrease in the EQ-5D score by one unit increased
the risk of NAFLD by more than threefold.
Indication of an increased risk of NAFLD (by
1.3 times) in individuals with increased
perceived stress.
Kang et al. (2020)
[55] Korea
Cross-sectional Total:
N = 171,321 (male: 50.1%)
Mean Age: 39.8 ys
With NAFLD:
N = 47,538 (male: 76.6%)
Mean Age: 42 ys
Without NAFLD:
N = 123,783 (female: 60.1%)
Mean Age: 38.9 ys
NAFLD diagnosed by ultrasonography
Stress
PSI
An independent association between higher levels
of perceived stress and a greater prevalence of
NAFLD was identified.




N = 2367 (male: 100%)
Mean Age: 36.65 ys
NAFLD new onset:
N = 739 (male: 100%)
Mean Age: 36.9 ys
NAFLD non-onset:
N = 1628 (male: 100%)
Mean Age: 36.54 ys
Stress
OSI-R
High occupational stress and high personal strain
identified as independent risk factors for NAFLD.
Presence of NAFLD was significantly higher in
traffic police officers.
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Table 2. Cont.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed & Method Outcome/Main Findings
Russ et al. (2015)
[8] UK
Meta-analysis of Individual Study
Participants
N = 166,631 (female: 55%)
Mean Age: 46.6 ys
Stress
GHQ
Psychological distress associated with liver
disease mortality.







NAFLD patients have poorer HRQoL compared
with healthy controls.




N = 221 (female: 67.9%)
Mean Age: 54 ys
Hepatitis B:
N = 91 (male: 56%)
Mean Age: 45.9 ys
AILD:
N = 43 (female: 90.7%)
Mean Age: 49.3 ys
HRQoL
CLDQ
CLDQ and HRQoL scores were significantly lower
for patients with NAFLD and AILD compared
with HBV.




N = 106 (female: 69.8%)
Mean Age: 46.4 ys
Hepatitis B:
N = 56 (male: 73,2%)
Mean Age: 45.4 ys
Hepatitis C:
N = 75 (male: 57.3%)
Mean Age: 47.0 ys
HRQoL
CLDQ
Patients were identified from the Liver Disease
Quality of Life Database. HRQoL scores were
significantly lower for NAFLD patients compared
with patients with hepatitis B or hepatitis C on
multiple CLDQ domains.
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Table 2. Cont.
Study [Reference] Country Study Design/Cohort Mental Health Related OutcomeAssessed & Method Outcome/Main Findings




N = 3333 (male: 54.5%)
Mean Age: 51.31 ys
Controls:
N = 5982 (male: 51.8%)
Mean Age: 47.5 ys
NAFLD was determined by the FLI
HRQoL
HRQOL-4 NAFLD is associated with impaired HRQoL.
Tapper & Lai (2016)
[70] USA
Prospective longitudinal study
N = 151 (male: 60%)




At the 6-month follow-up of a weight loss
intervention programme, this study revealed that
patients achieving a 5% weight reduction showed
significantly improved HRQoL.
Funuyet-Salas et al. (2020)
[92] Spain
Cross-sectional
N = 492 (male: 58.9%)









Low perceived social support, significant fibrosis,
and female sex were independently associated
with a higher-risk psychosocial profile in NAFLD.
AILD: Autoimmune liver disease; BDI: Beck Depression Inventory; BD-II: Beck Depression Inventory II; CES-D: Centre for Epidemiological Studies—Depression; CLDQ: Chronic Liver Disease Questionnaire;
COPE-28: Brief COPE (28-item self-reporting measure of coping styles in response to a stressful experience); DSM-IV: Diagnostic and Statistical Manual of Mental Health Disorders IV; EQ-5D: EuroQol 5
dimensions; FIB-4: fibrosis-4 score; FLI: fatty liver index; GHQ: general health questionnaire; HADS: Hospital Anxiety and Depression Scale; HSI: hepatic steatosis index; HRQOL: Health-Related Quality of Life;
HBV: hepatitis B virus; HCV: hepatitis C virus; ICD: International Classification of Diseases; MSPSS: Multidimensional Scale of Perceived Social Support; OSI-R: Occupational Stress Inventory-Revised; PHQ-9:
Patient Health Questionnaire; PSI: perceived stress inventory; SF-12: 12 item Short Form Health Survey; US: ultrasonography; USFLI: US fatty liver index; ys: years.
Biomedicines 2021, 9, 1697 20 of 25
Based on the broader relevant literature, additional parameters, such as emotional
loneliness, may also be involved in the noted associations between mental health problems
and NAFLD [32]. Thus, a broader understanding of the individual’s circumstances and
coping strategies may prove valuable [104,105]. Indeed, it is important to consider a
broad number of biological and psychological underlying factors that might play a role
in the interplay of associations between affective disorders and NAFLD. For example, in
future research, the notion of social support and coping strategies should be taken into
consideration, given their associations with physical and psychosocial outcomes for a range
of disorders. Interestingly, a recent study by Funuyet-Salas et al. [106]—which attempted to
identify factors that might have an influence on HRQoL, mental health status, and coping
strategies in a population of Spanish individuals with NAFLD—showed a higher risk of
psychosocial problems in female patients who indicated low levels of perceived social
support and who presented with significant fibrosis. As such, the study authors suggested
that factors relating to mental health, HRQoL, and coping strategies could play a role in
the management of patients with NAFLD, and that the potential advantages of relevant
psychological interventions should be considered in clinical practice [106].
Overall, despite its increasing prevalence globally, NAFLD has received much less
attention than other chronic non-communicable diseases with respect to potential bidi-
rectional links to mental health and HRQoL. Of note, for obesity-related diseases, such
as NAFLD, there is potentially an additional element of a self-blame perception, which
may also lead to shame and stigma, preventing the individual from seeking appropriate
help [1]. As such, there is a current discussion regarding the potential benefits of changing
the relevant terminology from NAFLD to MAFLD (metabolic-associated fatty liver dis-
ease), following a recent consensus of international experts [107,108]. In this context, it is
argued that the current NALFD terminology carries certain negative messages and could
be associated with stigmatization and trivialization. This may be addressed by adopting
the term MAFLD, which could potentially lead to a reduction in the existing negativity,
and might aid in better understanding/re-defining this highly prevalent disorder.
In conclusion, NAFLD is a growing problem globally, which deserves further atten-
tion for certain aspects of its pathophysiology, particularly regarding underlying links to
depression, anxiety, and stress. Elucidating such associations may help the prevention
and/or management of NAFLD in routine clinical practice, especially as specific NAFLD
treatments are currently lacking. Notably, it is possible that a feed-forward vicious cycle
exists between these prevalent mental health conditions and NAFLD, whereby depression,
anxiety and/or chronic stress may promote NAFLD, and vice versa. Recognizing and
breaking this potential vicious cycle in the clinical practice, as well as strengthening mental
health awareness in NAFLD-related primary and secondary care pathways, may have
substantial benefits for the interventions against NAFLD.
A key limitation of the present review is that the relevant searches focused only on
two databases (PubMed and Google Scholar) and on papers published only in English
mostly within the past decade, thus relevant papers not meeting these criteria may have
been omitted. Nonetheless, the present review highlighted important existing evidence
pertaining to linkages between the highly prevalent mental health problems of depression,
anxiety, and chronic stress and both NAFLD and metabolic syndrome. Furthermore, as
aforementioned, causation is difficult to determine in this context, and there might be
various reasons why two or more conditions may co-exist [26]. As there is no health and
wellbeing without mental health [109], further research is clearly needed in this field, and
could help in the development of appropriate complex interventions for addressing the
interrelated underlying pathophysiologic mechanisms and risk factors. Such interventions
should also incorporate a theoretical framework to promote the incorporation of a compas-
sionate approach, further targeted towards addressing the patient’s individual lifestyle,
confidence levels, and available coping strategies, and aimed at reducing any perceived
stigma that such patients might experience.
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